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ABSTRACT 
Indonesia as a potential maritime country in fish production, can be processed into fish oil containing omega-3. Based on 
previous libraries, omega-3 fish oils can be used to improve asthma control and improve lung function. The effects of a 
drug are individualized depending on genetic and environmental factors. The aim of the study was to investigate the effect 
of fish oil containing omega-3 on improving asthma symptoms and improving lung function. The research method used is 
pre-post test design, using data collection technique with asthma control test questionnaire to see clinical symptoms of 
asthma and measure lung function with peak flow meter. Intervention given is a fish oil product with once daily doses, 
then follow up every week for 4 weeks. The subject of research is adult age. Pulmonary function data and asthma symptoms 
will be tested for normality with shapiro-wilk test and followed by anova one way. The research was conducted in 2016-
2017 in Surabaya and the data obtained 28 respondents. At the control level of asthma and total ACT score (P <0.05) it can 
be concluded that there was significant difference between before and after omega-3 fish oil therapy for 4 weeks. In the 
improvement of lung function there is a significant improvement of lung function starting from before therapy until the 
increase every week until the 4th week. Fish oil containing omega 3 for 4 weeks may decrease asthma symptoms in the 
asthma control level category and total ACT score. In addition, fish oil can also improve lung function significantly in 
every week. 
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INTRODUCTION 
Asthma is a heterogeneous disease in the form of chronic 
respiratory tract inflammation characterized by respiratory 
symptoms such as wheezing, shortness of breath, feeling 
depressed in the chest and cough. Despite the low level of 
fatality but the number of cases is quite common in the 
community. The World Health Organization (WHO) 
estimates that 100-150 million people worldwide suffer 
from asthma. Even this number is expected to continue to 
grow to reach 180,000 people every year1-2. Adverse 
effects of asthma include decreased quality of life, 
decreased productivity, school absenteeism, increased 
healthcare costs, hospital care risks and even death3. 
Increases in the prevalence of asthma in Asia such as 
Singapore, Taiwan, Japan or South Korea are also striking. 
The incidence of asthma has increased over fifteen years, 
both in developing and developed countries. In Indonesia, 
the prevalence of asthma is not known for certain, but it is 
estimated that 2-5% of Indonesia's population suffers from 
asthma. The Department of Health estimates that asthma is 
among the top 10 causes of illness and mortality in 
hospitals and an estimated 10% of Indonesia's 25 million 
people suffer from asthma. The prevalence of asthma in 
urban areas is generally higher than in rural areas, as urban 
lifestyle increases the risk of asthma. According to 
RISKESDAS (2013) asthma prevalence in Indonesia 
reached 4.5% with asthma prevalence in East Java 5.1%4-
5. 
In Indonesia, which is a maritime country, has great 
potential in fish production and even the government 
also launched GEMARIKAN in 2014, to popularize fish 
consumption. Fish has been known to be processed into 
fish oil containing high omega-3. Fish consumption can 
prevent asthma in adult patients. Research has shown 
that fish consumption at least once a month can reduce 
the risk of asthma6. In the meantime, several fish oil-
related studies, including omega-3s as Aprizayanti 
(2011)7 and Santoso et al. (2013)8. Omega-3 has been 
used only as a supplement in helping the child's growth 
process, help lower cholesterol, heart disease. High 
intake of fish oil has protective effect against asthma 
and or allergies9. Omega-3 polyunsaturated fatty acids 
(n-3 PUFAs) consisting of eicosapentaenoic acid (EPA) 
and docosahexaenoic acid (DHA) are found primarily in  
Amelia et al. / Effectiveness of Fish… 
 
 
                                             IJPQA, Volume 9, Issue 3, July 2018 – September 2018                                          Page 261 
fish oil. Epidemiological studies show that omega-3 has  
a protective effect against cardiovascular disease 
myocardial infarction or cerebral infarction, 
hypertension, and hyperlipidemia. In addition, omega-3 
has beneficial effects on chronic inflammatory diseases 
including chronic obstructive pulmonary disease 
(COPD), asthma, rheumatoid arthritis, and 
inflammation of the intestine. Atopic sensitization and 
allergies can also be prevented with fish intake during 
pregnancy10. 
In Indonesia has conducted several studies related to fish 
oil, which among others contain omega-3. Omega-3 is 
used as a supplement in helping the child's growth process, 
help lower cholesterol, heart disease7,8,10,11,12. But there has 
been no research related to the effect of omega-3 on the 
improvement of asthma in Indonesia. The anti-
inflammatory effect on omega-3 is due to the content of 
EPA which is a competitive substrate with arachidonate so 
it has the potential to reduce inflammation of the 
respiratory tract and bronchoconstriction. This has led to a 
new understanding over the last 30 years that fish oil 
deficiency can aggravate asthma13. 
This study aims to determine the effect of omega-3 on the 
control of asthma in patients with asthma in Surabaya who  
Table 1: Frequency Distribution of Respondent Characteristics. 
Characteristics Number (n: 26) Percentage (%) 
Gender Male 7 27,00 
Female 19 73,00 
Age (years) Youth end (17-25) 25 96,15 
Early adult (26-35) 1 3,85 
Late adult (36-45) 0 0,00 
History of Asthma 
Treatment based on 
Global Initiative for 
Asthma (2016)1 
Oral agonist beta-2 short acting  8 21,05 
Inhaled agonist beta-2 short acting  10 26,31 
Oxygen 1 2,63 
Not taking any medication 3 7,89 
Oral corticosteroids (used only when symptoms 
worsen) 
1 2,63 
Oral  methylxanthine  (used only when symptoms 
worsen) 
3 11,53 
    
Table 2: Frequency Distribution Assessment of Asthma Symptoms Based on ACT. 
Asthma Assessment Category Number of Respondents 
ACT0 ACT4 
Asthma Control Based on 
Activity Limitations  
Every now and then 1 0 
Too often 0 0 
Often 2 4 
Not too often 14 16 
Never 9 6 
Asthma Control Based on 
Frequency of Shortness of 
Breath 
More than once a day 0 0 
Once a day 0 0 
3-6 times a week 5 3 
Once or twice a week 14 14 
Not a week at all 7 9 
Asthma Control Based on 
Symptoms Symptom Asthma 
At Night or Morning 
4 or more nights per week 2 2 
2-3 nights per week 3 1 
once a week 4 0 
Once or twice 6 14 
not at all 11 9 
Asthma Control Based on 
Frequency of Asthma Drug 
Use 
3 or more per day 1 0 
1 or 2 times per day 2 3 
2 or 3 times per week 4 5 
Once a week or less 5 4 
not at all 14 14 
Asthma Control Based on 
Asthma Control Level 
Not controlled at all 8 3 
Less controlled 6 5 
Simply controlled 6 8 
Well controlled 4 6 
Full controlled 0 4 
ACT Total Uncontrolled (total value of ACT: <19) 17 11 
Partially controlled (total value ACT: 20-24) 5 13 
Full controlled (total value ACT: 25) 4 2 
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will be given fish oil. During this treatment asthma focuses  
on therapy with long-term synthetic drugs, which can  
cause problems such as: the use of aminophylline which is 
a drug with a narrow range of therapy so that the risk of 
causing side effects14,15,16, single use of long-acting beta-2 
agonist that can aggravate Exacerbation of asthma17, or the 
use of inhaled corticosteroids that may cause 
oropharyngeal candidiasis and even lung infections1. 
This study aims to determine the effect of fish oil 
containing omega-3 to improve asthma symptoms and 
improve lung function. Patients with a high level of 
education influence self evaluation so that it can affect the 
patient's asthma control level. This study uses research 
subjects with a minimum education level of high school 
with the hope that the level of asthma control is good, and 
is expected this study can also increase knowledge related 
to the influence of nutrition on asthma, in the role of 
pharmacist to support the handling of asthma by 
motivating patients to be obedient in treatment, Provide 
information, counseling, and education so that they better 
understand the treatment regimen provided so that patients 
can be more actively involved in their treatment which can 
improve their adherence to drug use. Treatment of asthma 
is a long-term treatment and adherence to medication and 
treatment is desirable. It is expected that good patient 
compliance will affect the number of drugs used less, 




This research uses pre-post test design method. This study 
used data collection techniques with Asthma Control Test 
questionnaire to see clinical symptoms of asthma and 
measure lung function with peak flow meter tool. Each 
sample of the study was given fish oil. Intervention given 
is a fish oil products circulating in Indonesia. Fish oil is 
given to patients with once daily doses, then follow up 
every week for 4 weeks. Dosage of fish oil containing  
Table 3: ACT Normality Assessment Test Group Intervention 
Asthma Assessment Category P value 
ACT0 ACT4 Conclusion 
Activity Limitations 0,00 0,00 Distribution of data is not normal 
Frequency of Shortness of Breath 0,00 0,00 Distribution of data is not normal 
Asthma Symptoms At Night or Morning 0,00 0,00 Distribution of data is not normal 
Frequency of Asthma Drug Use 0,00 0,00 Distribution of data is not normal 
Level of asthma control 0,001 0,044 Distribution of data is not normal 
ACT Total 0,558 0,460 Distribution of data is normal 
P> 0.05 means normal distribution; P <0.05 means the distribution is not normal 
 
Table 4: Changes in ACT Value as Asthma Symptoms 
Asthma Assessment Category Number of Respondents 
Change the value of ACT0 to ACT4 
Up Constant Down 
Activity Limitations 5 15 6 
Frequency of Shortness of Breath 6 18 2 
Asthma Symptoms At Night or Morning 6 17 3 
Frequency of Asthma Drug Use 4 17 5 
Level of asthma control 16 9 1 
ACT Total 15 6 5 
    
Table 5: ACT Differences Test Before and After Omega-3 Fish Oil Therapy. 
Asthma Assessment Category Average Test the Difference 
ACT0 ACT4 P value Type of Test Used Conclusion 
Activity Limitations 3,81 4,08 0,763 Friedman Test There is no significant 
difference 
Frequency of Shortness of 
Breath 
4,08 4,23 0,157 Friedman Test There is no significant 
difference 
Asthma Symptoms At Night or 
Morning 
3,81 4,04 0,317 Friedman Test There is no significant 
difference 
Frequency of Asthma Drug Use 4,12 4,12 0,739 Friedman Test There is no significant 
difference 
Level of asthma control 2,08 3,12 0,00 Friedman Test There is a significant 
difference 
ACT Total 17,89 19,58 0,041 Anova One Way There is a significant 
difference 
P> 0.05, Ho accepted means there is no significant difference 
P <0.05, Ho rejected means there is a significant difference 
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omega-3 recommended by 1 gram to 5.4 gram per day18, 
then in this study selected fish oil with dose of 1.0 gram. 
The independent variable of this research is fish oil. While 
the dependent variables of this study are symptoms of 
asthma and lung function, with controlled variables 
according to inclusion and exclusion criteria.  
Symtoms of asthma: Symptoms of asthma were measured 
by using the Asthma Control Test (ACT) questionnaire. 
ACT is one of the specific instruments in assessing asthma 
control in patients with chronic asthma. Consisting of 5 
questions that include activity limitation, shortness of 
breath, asthma symptoms at night, frequency of reliever 
drug use, and asthma control rate counted for 4 weeks. 
Each question is given a choice of 5- Likert 1,19. Symptoms 
of asthma were measured 2 times, ie, at week 0 (before 
intervention) and at week 4 (after intervention). Initials to 
use: 
ACT0: The value of ACT at week 0, ie before getting fish 
oil therapy contains omega-3 
ACT4: The value of ACT at week 4, ie after getting fish oil 
therapy containing omega-3 for 4 weeks (one month) 
Lung function: Pulmonary function is measured from the 
Peak Expiratory Flow (PEF) value. PEF is the maximum 
ability to expel air in the lungs from the maximum 
inspiratory state through the mouth in liters per minute 
units measured by peak flow meter which is a simple and 
easy to apply tool 1. Pulmonary function is measured 5 
times, ie once before the intervention and 3 times During 
intervention (after 1 week, 2 week, and 3 week 
intervention), and after intervention. Initials to use: 
PEF0: PEF value at week 0, ie before getting fish oil 
therapy contains omega-3 
PEF1: PEF value at week 1st, after getting fish oil therapy 
containing omega-3 for 1 week 
PEF2: The value of PEF at week 2nd, ie after getting fish 
oil therapy contains omega-3 for 2 weeks 
PEF3: PEF value at week 3rd, ie after getting fish oil 
therapy containing omega-3 for 3 weeks 
PEF4: PEF value at week 4th, ie after getting fish oil 
therapy containing omega-3 for 4 weeks (one month) 
The population of this study were adult asthma patients (> 
18 years) in Surabaya. The sample (subject) of the study 
were adult asthma patients who were willing to engage in 
research and meet the requirements, namely: (1) no 
chronic diseases that can affect respiratory function (such 
as chronic respiratory illness, heart disease, chronic renal 
failure, etc.); (2) No smoking or consuming alcohol; and 
(3) not taking routine asthma medication. 
Pulmonary function data and asthma symptoms will be 
tested the normality of data distribution by using shapiro-
wilk test. If p> 0,05 then it can be concluded that normal 
distribution data and then proceed with one way anova to 
know the improvement of lung function and clinical 




The research was conducted in 2016-2017 in Surabaya. 
The data used in this study were obtained through the 
asthma control test (ACT) questionnaire given at the 
beginning of the first week and the end of the 4th week, 
peak expiratory flow (PEF) measured weekly for 5 weeks. 
Based on the data obtained 28 respondents, but 2 people 
dropped out due to allergy to fish oil and resigned because 
out of town, then only 26 people who can follow the 
research. 
Characteristics of Respondents 
Respondents in this study were grouped by sex, age, and 
medical history. The number of respondents based on the 
characteristics of respondents includes age and gender. In 
the age category, the largest number is the final adolescent 
(17-25 years old) that is equal to 96.15% or a number of 
25 people and the largest number of female respondents is 
73% or 19 respondents from the total of 26 respondents. 
The largest number was in the respondents who used a 
group of agonist beta-2 short inhalation work of 26.31% in 
step 1 (Table 1). 
Improvement of Asthma Symptoms with Fish Oil Therapy 
Containing Omega-3 
Characteristics of respondents can be seen in table 2 with 
the depiction of each category ACT. Most of the symptoms 
of respondent asthma in three categories, namely: based on 
activity limitations, frequency of shortness of breath, 
frequency of asthma drug use, showed no change. But in 
most asthma symptoms based on asthma symptoms 
appearing in the evening or morning shows a decrease 
from the point "not at all" to "once up to two times". While 
asthma symptoms based on the level of control of 
respondents asthma increased. Based on the total of the 
overall ACT score, it showed improvement of most 
respondents with uncontrolled asthma symptoms being 
partially controlled (Table 2). 
Normality tests across all ACT categories show all data not 
normally distributed, except for the total ACT values 
showing normal distributed data (Table 3). 
The change in the value of asthma symptoms was divided 
into 3, ie "up" (there was an increase in ACT values after 
4 weeks of fish oil), "fixed" (no change in ACT values after 
4 weeks of fish oil) and "down" There was a decrease in 
ACT value change after being given fish oil for 4 weeks).  
Tabel 6: Average PEF Value and Normality Test for Lung Function Data 
Group Average PEF Value 
(L/sec) 
Test Data Normality 
Type of Test Used P value Conclusion 
PEF0 217,96 Shapiro wilk 0,002 No normal 
PEF1 273,15 Shapiro wilk 0,131 Normal 
PEF2 295,56 Shapiro wilk 0,109 Normal 
PEF3 298,89 Shapiro wilk 0,209 Normal 
PEF4 325,00 Shapiro wilk 0,089 Normal 
P> 0.05 means normal distribution; P <0.05 means the distribution is not normal 
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From table 4, it can be concluded that most improvements 
in asthma symptoms are seen only in the asthma level 
control category, whereas other categories show a fixed 
value. However, when viewed from the total value of ACT, 
showed most respondents experienced improvement 
(Table 4). 
Test the difference of asthma symptoms based on ACT 
value before and after fish oil therapy in table 5. At the 
control level of asthma and total ACT value (P <0,05) it 
can be concluded that there was significant difference 
between before and after fish oil therapy containing 
omega-3 For 4 weeks (Table 5). 
Improvement of Lung Function with Omega-3 Fish Oil 
Therapy 
The Difference Test describes the average PEF score 
obtained once a week after the respondents get a fish oil 
intervention for 4 weeks. The largest number was in the 
intervention group at week 4 with an average of 325,00 
(Table 6). 
Based on the normality test from table 6 indicating that 
there is data showing abnormal distribution (PEF0 data), 
the difference test using Friedman Test (Table 7). Based 
on the difference test, it was concluded that there was a 
significant improvement on every week (Table 7). 
 
DISCUSSION 
Discussion of Asthma Symptoms Improvement 
The results showed changes in ACT values that increased 
from uncontrolled conditions before treatment were then 
partially controlled after therapy. This is consistent with 
existing libraries that the omega-3 content of fish oil 
containing fatty acids has a beneficial effect on chronic 
inflammatory diseases including chronic obstructive 
pulmonary disease (COPD), asthma, rheumatoid arthritis, 
and inflammatory diseases18. Fish oils containing omega 3 
comprising EPA and DHA suppress the production of 
arachidonic acid through the ALOX5 pathway. 
Arachidonic acid is a substrate for eicosanoid synthesis 
that produces an inflammatory mediator consisting of 
CYS-LT, prostaglandin, and thromboxane. This mediator 
is involved in the bronchoconstriction process and 
improves the respiratory tract mucus in asthma patients. 
EPA-enriched fish oil can inhibit the competitive 
production of LTC4 with arachidonic acid that acts as an 
ALOX5 substrate. EPA can also suppress an allergic 
response to asthma by inhibiting arachidonic acid that 
produces leukotrienes. Leukotriene and prostaglandin E2 
contribute to the formation of immunoglobulin E (IgE), an 
antibody that contributes to the occurrence of an allergic 
response. This is usually increased in patients with 
asthma13. Although the respondents experienced an 
improvement in ACT scores, there were several factors 
that could affect the value of ACT, among others:  
Gender and age: In table 1, shows the largest number of 
samples are women than men. In boys have a greater risk 
in infancy and this risk decreases as they mature. While in 
women have a risk of staying in childhood and adulthood. 
The prevalence of women is higher than men, but the 
reason for the difference is not clear. However, at birth, 
men's lung size is smaller than women but as adults are 
larger. The risk of asthma in boys decreases as they grow 
older. While in women, the influence of estrogen and 
progesterone hormones can cause high asthma risk in 
women during and after puberty20. Similarly, the National 
Center for Health Statistics (NCHS) (2011)21, which says 
by sex 7,2% of men and 9,7% of women that the 
prevalence of women is higher than men. Respondents in 
this study were mostly in the final adolescent category with 
age 17-25 years.  
Genetic Factors: There is a relationship between ALOX5's 
genetic polymorphism and the severity of asthma, whereas 
ALOX5 is the code of the enzyme that produces 
leukotriene, which plays the role of the severity of asthma. 
Genetic polymorphisms of ALOX5 as well as 5-
lipoxygenase-activating protein (FLAP) are associated 
with excessive production of leukotrienes. ALOX5 and 
FLAP are increased RNA messenger in peripheral blood 
leukocytes in asthmatics and leukotriene concentrations in 
Table 7: Changes in PEF Value and Pef Value Differences Test Before and After Omega-3 Fish Oil Therapy. 
Compared groups Jumlah Responden Uji Perbedaan 
Changes in PEF Value (L/sec) P value Type of Test Used Conclusion 
Up Constant Down 
PEF0 and PEF1 20 2 5 0,014 Friedman Test There is a significant 
difference 
PEF0 and PEF2 21 1 5 0,003 Friedman Test There is a significant 
difference 
PEF0 and PEF3 20 1 6 0,009 Friedman Test There is a significant 
difference 
PEF0 and PEF4 24 1 2 0,00 Friedman Test There is a significant 
difference 
PEF1 and PEF2 20 0 7 0,00 Anova One Way There is a significant 
difference 
PEF2 and PEF3 16 2 9 0,013 Anova One Way There is a significant 
difference 
PEF3 and PEF4 21 0 6 0,017 Anova One Way There is a significant 
difference 
P> 0.05; Ho rejected means there is no significant difference 
P <0.05; Ho accepted means there is a significant difference 
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sputum are greater in asthma patients compared with non-
asthma13.  
Environmental factors (eg trigger exposure): To minimize 
the influence of environmental factors in this study 
respondents will always be required to report their 
activities during fish oil therapy, as factors such as contact 
with triggers, diet, excessive physical activity, etc. may 
affect the control of asthma symptoms.  
Other therapies used. In the treatment history, most of the 
samples used inhaled beta-2 agonist drug inhalation group 
and all respondents were at step 1 treatment. Asthma 
treatment is divided into controller and reliever. Controller 
is a daily-used treatment in the long term to keep asthma 
under clinical control through its anti-inflammatory 
effects. While reliever is a treatment that is used when 
necessary and quickly to reduce bronchoconstriction and 
reduce the acute symptoms that accompany it. In this 
study, all respondents were at step 1, which means that 
none of the respondents used controller asthma medication 
to maintain their daily asthma control, and all respondents 
only used asthma medications when experiencing 
worsening symptoms (reliever). The main choice in this 
type of reliever is a short action beta-2 agonist which is 
generally salbutamol with inhalation route. Inhalation 
routes are preferred because they are topical, so side effects 
tend to be smaller and can work directly to the target site 
in the bronchioles. However, from the data of treatment 
used by respondents there are some respondents who use 
corticosteroids (oral or inhalation) and methylxanthine 
group which is actually an asthma therapy in the controller 
group1. 
Discussion of Lung Function Repair  
From the research results can be seen that there is an 
increase in PEF value between the data before and after the 
patient get therapy. This indicates a potential effect after 
the respondents are given intervention in the form of fish 
oil. Improvement of asthma function may be influenced by 
other uncontrollable factors in research such as 
psychological (stress)22,23, unpredictable weather changes 
(such as cold or windy air)24,25 and daily activities26. 
During the measurement of PEF values, Which can be 
minimized the activity of respondents because it is done at 
the same time. The factors that affect the value of PEF but 
can be controlled in this study include food and drugs 
consumed. Foods such as fish that contain high protein can 
cause bias research results. And drugs like asthma 
medication can increase the value of PEF. However, it can 
be controlled from the presence of a log book given to the 
patient to be filled daily containing the activities carried 
out, drugs and food consumed, and adherence during the 
consumption of fish oil. 
Limitations of Research 
Criteria for inclusion of respondents such as heart and 
kidney history data were not accurately obtained. Because 
when respondents say that no history of heart and kidney 
is not supported by the results of checking the doctor first 
by using electrocardigram (ECG) 
In this study using fish oil from a particular brand, which 
does not rule out the possibility that fish oil with other 
types can provide effects or not on research related asthma. 
Researchers use this type of fish oil because the dose 
corresponds to the desired dose of fish oil is 1.0 grams. 
Therefore, respondents feel less comfortable to consume 
fish oil that is considered quite large because some 
respondents commented on soft capsule large enough. 
Increased prevalence of asthma occurs due to genetic and 
environmental factors. Asthma is a complex disease 
resulting from the interaction between genetic 
predisposition and environmental factors. Both of these 
factors not only affect the inflammatory process but also 
affect the complex and interactive phenotype. 
The number of samples in this study were 26 people. 
Researchers have difficulty in finding a large number of 
samples to get valid results. Researchers should be able to 
work with health centers or other health agencies so that 
the number of samples can be reproduced. 
Researchers cannot control racial factors that can affect 
genetic outcomes. Therefore it is necessary to do further 
research related to genetic influence (polymorphism of 




Fish oil containing omega-3 for 4 weeks may decrease 
asthma symptoms in the asthma control level category and 
total ACT score. In addition, fish oil can also improve lung 
function significantly in every week. 
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